AlphaMadera
REGENXBIO Inc. (RGNX)
$8.07
-0.04 (-0.52%)Delayed quote.
Price history
Daily close- Start
- $11.02
- Latest close
- $8.07
- Period change
- -26.77%
- Period low
- $5.65
- Period high
- $15.98
Key metrics
- Market cap
- $500.38M
- Volume
- 97.5K
- Average volume
- 1.54M
- 52-week range
- $5.46 – $16.19
- Beta
- 0.93
- Last dividend
- —
- EPS (TTM)
- -$3.21
- P/E ratio
- -3.83
- Revenue (TTM)
- $153.91M
- Net income (TTM)
- -$175.23M
- Total assets
- $466.04M
- Total debt
- $66.55M
- Cash and equivalents
- $95.80M
Key financials (trailing twelve months).
Company profile
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- CEO
- Curran Simpson
- Employees
- 371
- Headquarters
- Rockville, MD, US
- IPO date
- 2015-09-17
- Website
- https://www.regenxbio.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Revenue | $170.44M | $83.33M | $90.24M |
| Gross profit | $150.14M | $49.76M | $53.03M |
| Operating income | -$161.20M | -$233.35M | -$268.13M |
| EBITDA | -$133.25M | -$198.23M | -$239.46M |
| Net income | -$193.88M | -$227.10M | -$263.49M |
| Diluted EPS | -$3.76 | -$4.59 | -$6.02 |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $34.47M | $57.53M | $34.52M |
| Total assets | $453.03M | $465.99M | $573.97M |
| Total liabilities | $350.30M | $206.34M | $262.23M |
| Total debt | $260.52M | $82.03M | $89.29M |
| Shareholders’ equity | $102.73M | $259.65M | $311.74M |
| Metric | FY2025Dec 31, 2025 | FY2024Dec 31, 2024 | FY2023Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$123.96M | -$173.12M | -$218.41M |
| Capital expenditure | -$2.41M | -$2.44M | -$9.96M |
| Free cash flow | -$126.38M | -$175.56M | -$228.37M |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.16M | $108.02M | $6.39M | $30.34M | $29.73M | $21.36M |
| Gross profit | $8.02M | $106.98M | -$4.68M | $24.41M | -$32.09M | $12.24M |
| Operating income | -$35.53M | $29.26M | -$83.36M | -$57.64M | -$52.41M | -$63.28M |
| EBITDA | -$29.75M | $34.26M | -$77.49M | -$51.00M | -$44.89M | -$55.97M |
| Net income | -$40.74M | $22.71M | -$90.05M | -$67.15M | -$61.94M | -$70.87M |
| Diluted EPS | -$0.62 | $0.43 | -$1.72 | -$1.30 | -$1.20 | -$1.38 |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $95.80M | $36.49M | $15.23M | $34.47M | $58.80M | $79.56M |
| Total assets | $466.04M | $386.62M | $341.89M | $453.03M | $525.20M | $581.03M |
| Total liabilities | $318.00M | $314.85M | $320.81M | $350.30M | $363.75M | $367.35M |
| Total debt | $66.55M | $68.95M | $71.07M | $260.52M | $268.14M | $77.70M |
| Shareholders’ equity | $148.04M | $71.77M | $21.08M | $102.73M | $161.45M | $213.68M |
| Metric | Q3 2026Sep 30, 2026 | Q2 2026Jun 30, 2026 | Q1 2026Mar 31, 2026 | Q4 2025Dec 31, 2025 | Q3 2025Sep 30, 2025 | Q2 2025Jun 30, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $38.61M | -$62.24M | -$76.19M | -$52.29M | -$55.96M | -$49.34M |
| Capital expenditure | -$194.0K | -$760.0K | -$1.24M | -$508.0K | -$491.0K | -$391.0K |
| Free cash flow | $38.41M | -$63.00M | -$77.42M | -$52.80M | -$56.45M | -$49.73M |